Patient has an unresolved ? Grade  adverse event (AE) from a previous antineoplastic treatment, excluding alopecia and phlebitis
Unresolved acute toxicity from prior anticancer therapy
Unresolved toxicity from prior chemotherapy (subjects must be recovered to ? Grade  toxicity from previous anticancer treatments or previous investigational products.
Unresolved chronic toxicity > grade  from prior therapy
Unresolved toxicity higher than CTCAE (v. .) Grade  attributed to any prior therapy/procedure excluding alopecia and hypothyroidism;
Unresolved toxicity higher than CTCAE grade  attributed to any prior therapy/procedure excluding alopecia
Unresolved CTCAE >Grade  toxicity (other than stable toxicity) from previous anti-cancer therapy excluding alopecia.
Have any unresolved chronic toxicity with CTC AE grade >= , from previous anti-NF therapy, except for alopecia
Unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment
Patients with unresolved > Grade  toxicity associated with any prior antineoplastic therapy
Has unresolved toxicities from previous anticancer therapy
Patients with unresolved > Grade  toxicity associated with any prior antineoplastic therapy
Persistent, unresolved ?Grade  clinically significant drug-related toxicity (except alopecia, erectile impotence, hot flashes, libido, neuropathy) associated with previous treatment
Any unresolved toxicity (>= CTCAE grade ) from previous anti-cancer therapy, excluding alopecia
Any unresolved >= grade  pulmonary toxicity from previous anti-cancer therapy
Any unresolved grade  or higher toxicity from previous anti-cancer therapy
Unresolved grade  or greater toxicity from most recent treatment, including chemotherapy, hormonal therapy, or radiotherapy, at the time of study enrollment
Unresolved toxicity higher than NCI-CTCAE version . grade  attributed to any prior therapy/procedure excluding anemia or neuropathy grade  and alopecia of any grade
Have any unresolved chronic toxicity with CTCAE grade >= , from previous anti-NF therapy, except for alopecia
Unresolved toxicity higher than CTCAE grade  attributed to any prior therapy/procedure excluding alopecia
Unresolved toxicity from previous anticancer therapy or incomplete recovery from surgery
Any unresolved toxicity > CTCAE grade  despite optimal care/support, from previous anti-cancer therapy, except for alopecia, within  days prior to Cycle , day 
Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment
Any unresolved toxicity ? Grade  from previous anticancer therapy except for stable chronic toxicities (? Grade ) not expected to resolve.
Patients with unresolved > Grade  toxicity associated with any prior antineoplastic therapy
Unresolved toxicities from previous anticancer therapy.
Unresolved > Grade  toxicity associated with any prior antineoplastic therapy
Unresolved toxicity higher than CTCAE grade  attributed to any prior therapy/procedure, excluding alopecia
Subjects experiencing unresolved toxicity of previous antitumor therapy which is CTCAE grade >  before the start of study treatment, except for alopecia or hemoglobin >= . g/dL or >= . mmol/L
Any unresolved toxicity ? Grade  (except stable Grade  peripheral neuropathy or alopecia) from previous anticancer therapy
Subject has any unresolved toxicity Grade >  from previous anti-cancer therapy
Unresolved toxicities from prior anticancer therapy
Has unresolved toxicity of greater than or equal to CTCAE Grade  attributed to any prior therapies.
Unresolved toxicities from previous anticancer therapy
Any unresolved toxicity greater than Common Toxicity Criteria (CTC) grade  from previous anti-cancer therapy
Adverse effects due to prior therapy unresolved at randomization
Any unresolved toxicity > Common Toxicity Criteria Grade  (except alopecia) from previous anticancer therapy (including radiotherapy)
Any unresolved toxicity NCI CTCAE Grade ? from previous anticancer therapy
Unresolved toxicities from prior therapy
Unresolved toxicity greater than CTCAE (version .) grade  attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity =< grade 
Any unresolved toxicity NCI CTCAE Grade ? from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criterion;
Significant unresolved toxicities from previous anticancer therapy that have not resolved, or have not stabilized at a new baseline
Unresolved toxicities from prior anticancer therapy
Any unresolved toxicity NCI CTCAE Grade ? from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criterion
Any unresolved toxicity CTCAE >Grade  from the prior chemoradiation therapy.
Unresolved toxicity higher attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin- induced neurotoxicity ? Grade  for at least  days;
Any unresolved toxicity CTCAE >Grade  from previous anti-cancer therapy.
Unresolved toxicity from other agents. Patients with unresolved Common Terminology Criteria for Adverse Events (CTCAE) version (v). grade  or greater toxicity from prior administration of another investigational drug and/or anti-cancer treatment are not eligible.
Unresolved toxicity higher than CTCAE v. . grade  attributed to any prior therapy/procedure excluding alopecia and oxaliplatin-induced neurotoxicity (which must be =< grade )
Any unresolved toxicity greater or equal to grade  from previous anticancer therapy, except for stable chronic toxicities not expected to resolve
Patients with any unresolved toxicity greater than Grade  from previous anticancer therapy
Unresolved toxicity higher than CTCAE v. . grade  attributed to any prior therapy/procedure excluding alopecia and oxaliplatin-induced neurotoxicity (which must be =< grade )
Any unresolved toxicity (> CTCAE grade ) from previous anti-cancer therapy
Has any unresolved toxicity ? Grade  from previous anticancer therapy
Subjects experiencing unresolved toxicity of previous antitumor therapy (excluding alopecia) which is CTCAE Grade > at screening
Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities greater than grade )
Any unresolved chronic toxicity greater then Common Terminology Criteria (CTC) grade  from previous anticancer therapy
Unresolved toxicities from prior anticancer therapy.
Patient with an unresolved ? Grade  AE from a previous antineoplastic treatment, excluding alopecia.
Patient has an unresolved ? Grade  AE from a previous antineoplastic treatment, excluding alopecia.
Unresolved clinically significant toxicity greater than Grade  from previous anti-cancer therapy
Has unresolved toxicity of greater than or equal to CTCAE Grade  attributed to any prior therapies
Unresolved toxicity higher than NCI-CTCAE version . Grade  attributed to any prior therapy/procedure (excluding alopecia or anemia or grade  neuropathy that is not reversible due to oxaliplatin)
Any unresolved >=Grade  (per CTCAE v .) toxicity from previous anti-cancer therapy at the time of enrollment, except alopecia or Grade  anemia (if hemoglobin is >. g/dL)
Unresolved, clinically significant toxicity from prior therapy, except for alopecia and Grade  peripheral neuropathy
Grade  or greater unresolved toxicity from prior antineoplastic therapy
Any unresolved toxicity greater than CTCAE grade  (except alopecia, and certain other unresolved CTCAE grade  toxicities including bone marrow hypocellularity, lymphopenia, infusion-related reaction, infusion site extravasation, injection site reaction, portal vein hypertension, obesity) from previous anti-cancer therapy; patients with grade  neuropathy will be evaluated on a case by case basis for entry into study; pre-chemotherapy medical conditions will be taken into consideration
Patient experiencing unresolved toxicity ? CTCAE grade  (except alopecia) from previous agents.
Any unresolved chronic toxicity greater than CTC grade  from previous anticancer therapy (except alopecia)
Unresolved toxicities from prior therapy
Unresolved toxicity from other agents; participants with unresolved or unstable Common Toxicity Criteria Adverse Event version  (CTCAE v) grade  or greater toxicity from prior administration of another anti-cancer treatment are not eligible
Unresolved chronic toxicity of previous AML treatment
Has unresolved toxicities from previous anticancer therapy
Unresolved specific chronic toxicity of previous treatment of grade >  except for alopecia or hemoglobin ?. g/dL (or ?. mmol/L)